These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 28188776)
1. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776 [TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Kruiswijk F; Hasenfuss SC; Sivapatham R; Baar MP; Putavet D; Naipal KA; van den Broek NJ; Kruit W; van der Spek PJ; van Gent DC; Brenkman AB; Campisi J; Burgering BM; Hoeijmakers JH; de Keizer PL Oncogene; 2016 Apr; 35(17):2166-77. PubMed ID: 26279295 [TBL] [Abstract][Full Text] [Related]
3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
4. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685 [TBL] [Abstract][Full Text] [Related]
5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
6. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597 [TBL] [Abstract][Full Text] [Related]
7. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
9. miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A. Chang X; Zhang H; Lian S; Zhu W Biochem Biophys Res Commun; 2016 Jul; 475(3):251-6. PubMed ID: 27233613 [TBL] [Abstract][Full Text] [Related]
10. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Packer LM; East P; Reis-Filho JS; Marais R Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280 [TBL] [Abstract][Full Text] [Related]
11. KIT Suppresses BRAF Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418 [TBL] [Abstract][Full Text] [Related]
12. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037 [TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360 [TBL] [Abstract][Full Text] [Related]
15. FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Yang N; Wang C; Wang Z; Zona S; Lin SX; Wang X; Yan M; Zheng FM; Li SS; Xu B; Bella L; Yong JS; Lam EW; Liu Q Oncogene; 2017 Jun; 36(24):3428-3440. PubMed ID: 28114286 [TBL] [Abstract][Full Text] [Related]
16. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881 [TBL] [Abstract][Full Text] [Related]
19. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787 [TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]